BridgeBio Oncology Therapeutics witnessed a single proposed sale of 78 shares valued at 183.3 USD by officer Marc Cobo on November 13, 2026. This activity follows a recent earnings report showing a 33.8% EPS beat. The stock has experienced a 76.3% decline over the past ninety days, trading significantly below its annual peak.